( nincrease from around 300000 patients...)Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis,Health

n increase from around 300,000 patients in 2001. Potentially a further two to three times as many individuals may suffer from Ulcerative Colitis but are currently undiagnosed. Crohn’s Disease is more prevalent with an estimated 558,000 cases in the US in 2005. The US market for Ulcerative Colitis drugs was estimated to be US$420 million in 2002 and is expected to reach US$500 million by 2012, a CAGR of four percent. The US market for Crohn’s Disease drugs was estimated to be US$590 million, growing to around US$980 million by 2012. In both cases, the global market is estimated to be twice the size of the US. Global sales of Ulcerative Colitis drugs are estimated to reach US$1 billion by 2012 and, for Crohn’s Disease, the estimate is around US$2 billion. Current treatments include Aminosalicylates (5-ASAs) to reduce and control inflammation. In addition, Corticosteroids and Immunomodulators are prescribed for patients who do not respond to first line treatments.

About HMPL-004

HMPL-004 acts on multiple cellular targets in the inflammatory signal transduction pathways resulting in suppressed inflammation cytokine expression including TNF-?, IL-1? and IL-6. HMPL-004 was demonstrated to inhibit TNF-? and IL-1? production in cell-based assays. HMPL-004 is also able to inhibit NF-kB activation. NF-kB is a family of transcriptional factors that regulate a wide spectrum of genes critically involved in host defence and inflammation. The mechanism of action of HMPL-004 was further supported in inflammatory bowel disease pre-clinical models. Treatm
'"/>

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product